06/05/2026
💊 In recent years, a new generation of metabolic drugs has reshaped the treatment of obesity and type 2 diabetes.
Medications based on GLP-1 receptor agonists have shown significant effects not only on weight reduction but also on metabolic regulation.
More recently, clinical studies have suggested that these therapies may also provide cardiovascular benefits, reducing the risk of certain cardiac events.
These findings highlight the importance of approaching metabolic diseases through a broader systemic perspective.
Research is now exploring next-generation therapies combining multiple hormonal pathways.
🖇️ https://www.cqssalud.com/en/new-anti-obesity-drugs-that-are-also-transforming-cardiovascular-health/